目的 研究氟伐他汀聯(lián)合阿羅洛爾治療冠心病心力衰竭的臨床療效。方法 選取2013年2月—2015年1月石家莊市第三醫(yī)院心內(nèi)科收治的冠心病心力衰竭患者134例,隨機(jī)分為對(duì)照組和治療組,每組67例。對(duì)照組口服鹽酸阿羅洛爾片,10 mg/次,2次/d。治療組口服氟伐他汀鈉緩釋片,40 mg/次,1次/d,鹽酸阿羅洛爾片的用法用量同對(duì)照組。兩組患者均連續(xù)治療90 d。觀察兩組的臨床療效,同時(shí)比較兩組治療前后左心室射血分?jǐn)?shù)(LEVF)、左室舒張末期內(nèi)徑(LVDd)、舒張期室間隔厚度(dIVST)、平均動(dòng)脈壓(MAP)、心臟指數(shù)(CI)、每搏輸出量(SV)、每搏指數(shù)(SI)、肺動(dòng)脈楔壓(PAWP)、心率(HR)、體循環(huán)阻力(SVR)、肺循環(huán)阻力(PVR)的變化。結(jié)果 治療后,對(duì)照組和治療組總有效率分別為74.63%、92.54%,兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義(P < 0.05)。治療后,兩組患者LVEF、MAP、SV、SI均較治療前顯著升高,dIVST、HR、SVR顯著降低,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P < 0.05),且治療組這些觀察指標(biāo)的改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。結(jié)論 氟伐他汀聯(lián)合阿羅洛爾治療冠心病心力衰竭具有較好的臨床療效,可改善患者心功能相關(guān)指標(biāo),且無(wú)明顯不良反應(yīng),值得臨床推廣應(yīng)用。

Objective To observe the clinical effect of fluvastatin combined with arotinolol in treatment of coronary heart disease patients with heart failure. Methods Coronary heart disease patients (134 cases) with heart failure in Shijiazhuang the Third Hospital from February 2013 to January 2015 were randomly divided into control and treatment groups, and each group had 67 cases. The patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. The patients in treatment group were po administered with Fluvastatin Sodium Extended Release Tablets, 40 mg/time, once daily, and the usage and dosage of Arotinolol Hydrochloride Tablets were the same as control group. Two groups were treated for 90 d. After treatment, the efficacy was evaluated, and the changes of LEVF, LVDd, dIVST, MAP, CI, SV, SI, PAWP, HR, SVR, and PVR in two groups before and after treatment were compared. Results The efficacies in the control and treatment groups were 74.63% and 92.54%, respectively, and there were differences between two groups (P < 0.05). After treatment, LVEF, MAP, SV, and SI in two groups were significantly increased, while dIVST, HR, and SVR were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fluvastatin combined with arotinolol has the good clinical effect in treatment of coronary heart disease patients with heart failure, and can improve cardiac function related parameters with less adverse reactions, which is worth clinical promotion.